img

Global Neuromyelitis Optica Therapy Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neuromyelitis Optica Therapy Market Research Report 2024

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
According to Mr Accuracy reports new survey, global Neuromyelitis Optica Therapy market is projected to reach US$ 60 million in 2029, increasing from US$ 47 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neuromyelitis Optica Therapy market research.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neuromyelitis Optica Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Other

Segment by Application


Acute Attack
Remission Prophylactic Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Neuromyelitis Optica Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Other
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Therapy Market Perspective (2018-2029)
2.2 Neuromyelitis Optica Therapy Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neuromyelitis Optica Therapy Historic Market Size by Region (2018-2024)
2.2.3 Neuromyelitis Optica Therapy Forecasted Market Size by Region (2024-2029)
2.3 Neuromyelitis Optica Therapy Market Dynamics
2.3.1 Neuromyelitis Optica Therapy Industry Trends
2.3.2 Neuromyelitis Optica Therapy Market Drivers
2.3.3 Neuromyelitis Optica Therapy Market Challenges
2.3.4 Neuromyelitis Optica Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Therapy Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Therapy Players by Revenue (2018-2024)
3.1.2 Global Neuromyelitis Optica Therapy Revenue Market Share by Players (2018-2024)
3.2 Global Neuromyelitis Optica Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Therapy Revenue
3.4 Global Neuromyelitis Optica Therapy Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Therapy Revenue in 2022
3.5 Neuromyelitis Optica Therapy Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Therapy Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Therapy Breakdown Data by Type
4.1 Global Neuromyelitis Optica Therapy Historic Market Size by Type (2018-2024)
4.2 Global Neuromyelitis Optica Therapy Forecasted Market Size by Type (2024-2029)
5 Neuromyelitis Optica Therapy Breakdown Data by Application
5.1 Global Neuromyelitis Optica Therapy Historic Market Size by Application (2018-2024)
5.2 Global Neuromyelitis Optica Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Neuromyelitis Optica Therapy Market Size (2018-2029)
6.2 North America Neuromyelitis Optica Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Neuromyelitis Optica Therapy Market Size by Country (2018-2024)
6.4 North America Neuromyelitis Optica Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Therapy Market Size (2018-2029)
7.2 Europe Neuromyelitis Optica Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Neuromyelitis Optica Therapy Market Size by Country (2018-2024)
7.4 Europe Neuromyelitis Optica Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Therapy Market Size (2018-2029)
8.2 Asia-Pacific Neuromyelitis Optica Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Neuromyelitis Optica Therapy Market Size by Region (2018-2024)
8.4 Asia-Pacific Neuromyelitis Optica Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Therapy Market Size (2018-2029)
9.2 Latin America Neuromyelitis Optica Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Neuromyelitis Optica Therapy Market Size by Country (2018-2024)
9.4 Latin America Neuromyelitis Optica Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Therapy Market Size (2018-2029)
10.2 Middle East & Africa Neuromyelitis Optica Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2018-2024)
10.4 Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Therapy Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.1.5 Pfizer Recent Development
11.2 Fresenius
11.2.1 Fresenius Company Detail
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Therapy Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.2.5 Fresenius Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Therapy Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Detail
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Therapy Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.4.5 Sandoz Recent Development
11.5 Intas
11.5.1 Intas Company Detail
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Therapy Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.5.5 Intas Recent Development
11.6 Gyjtrs
11.6.1 Gyjtrs Company Detail
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Therapy Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.6.5 Gyjtrs Recent Development
11.7 NANG KUANG
11.7.1 NANG KUANG Company Detail
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Therapy Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.7.5 NANG KUANG Recent Development
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Detail
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Therapy Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.8.5 Tianjin Kingyork Recent Development
11.9 Baxter
11.9.1 Baxter Company Detail
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Therapy Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Detail
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Therapy Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Detail
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Therapy Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Detail
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Therapy Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.12.5 Octapharma Recent Development
11.13 CBOP
11.13.1 CBOP Company Detail
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Therapy Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Therapy Business (2018-2024)
11.13.5 CBOP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Glucocorticoids
Table 3. Key Players of Immunotherapies
Table 4. Key Players of Other
Table 5. Global Neuromyelitis Optica Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Neuromyelitis Optica Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Neuromyelitis Optica Therapy Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Neuromyelitis Optica Therapy Market Share by Region (2018-2024)
Table 9. Global Neuromyelitis Optica Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Neuromyelitis Optica Therapy Market Share by Region (2024-2029)
Table 11. Neuromyelitis Optica Therapy Market Trends
Table 12. Neuromyelitis Optica Therapy Market Drivers
Table 13. Neuromyelitis Optica Therapy Market Challenges
Table 14. Neuromyelitis Optica Therapy Market Restraints
Table 15. Global Neuromyelitis Optica Therapy Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Neuromyelitis Optica Therapy Market Share by Players (2018-2024)
Table 17. Global Top Neuromyelitis Optica Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Therapy as of 2022)
Table 18. Ranking of Global Top Neuromyelitis Optica Therapy Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Therapy Revenue (CR5 and HHI) & (2018-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuromyelitis Optica Therapy Product Solution and Service
Table 22. Date of Enter into Neuromyelitis Optica Therapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuromyelitis Optica Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2018-2024)
Table 26. Global Neuromyelitis Optica Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2024-2029)
Table 28. Global Neuromyelitis Optica Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2018-2024)
Table 30. Global Neuromyelitis Optica Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2024-2029)
Table 32. North America Neuromyelitis Optica Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Neuromyelitis Optica Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 34. North America Neuromyelitis Optica Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Neuromyelitis Optica Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Neuromyelitis Optica Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 37. Europe Neuromyelitis Optica Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Neuromyelitis Optica Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Neuromyelitis Optica Therapy Market Size by Region (2018-2024) & (US$ Million)
Table 40. Asia-Pacific Neuromyelitis Optica Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Neuromyelitis Optica Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Neuromyelitis Optica Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 43. Latin America Neuromyelitis Optica Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Neuromyelitis Optica Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 46. Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Neuromyelitis Optica Therapy Product
Table 50. Pfizer Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Fresenius Company Detail
Table 53. Fresenius Business Overview
Table 54. Fresenius Neuromyelitis Optica Therapy Product
Table 55. Fresenius Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 56. Fresenius Recent Development
Table 57. Teva Company Detail
Table 58. Teva Business Overview
Table 59. Teva Neuromyelitis Optica Therapy Product
Table 60. Teva Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 61. Teva Recent Development
Table 62. Sandoz Company Detail
Table 63. Sandoz Business Overview
Table 64. Sandoz Neuromyelitis Optica Therapy Product
Table 65. Sandoz Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 66. Sandoz Recent Development
Table 67. Intas Company Detail
Table 68. Intas Business Overview
Table 69. Intas Neuromyelitis Optica Therapy Product
Table 70. Intas Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 71. Intas Recent Development
Table 72. Gyjtrs Company Detail
Table 73. Gyjtrs Business Overview
Table 74. Gyjtrs Neuromyelitis Optica Therapy Product
Table 75. Gyjtrs Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 76. Gyjtrs Recent Development
Table 77. NANG KUANG Company Detail
Table 78. NANG KUANG Business Overview
Table 79. NANG KUANG Neuromyelitis Optica Therapy Product
Table 80. NANG KUANG Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 81. NANG KUANG Recent Development
Table 82. Tianjin Kingyork Company Detail
Table 83. Tianjin Kingyork Business Overview
Table 84. Tianjin Kingyork Neuromyelitis Optica Therapy Product
Table 85. Tianjin Kingyork Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 86. Tianjin Kingyork Recent Development
Table 87. Baxter Company Detail
Table 88. Baxter Business Overview
Table 89. Baxter Neuromyelitis Optica Therapy Product
Table 90. Baxter Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 91. Baxter Recent Development
Table 92. CSL Company Detail
Table 93. CSL Business Overview
Table 94. CSL Neuromyelitis Optica Therapy Product
Table 95. CSL Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 96. CSL Recent Development
Table 97. Grifols Company Detail
Table 98. Grifols Business Overview
Table 99. Grifols Neuromyelitis Optica Therapy Product
Table 100. Grifols Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 101. Grifols Recent Development
Table 102. Octapharma Company Detail
Table 103. Octapharma Business Overview
Table 104. Octapharma Neuromyelitis Optica Therapy Product
Table 105. Octapharma Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 106. Octapharma Recent Development
Table 107. CBOP Company Detail
Table 108. CBOP Business Overview
Table 109. CBOP Neuromyelitis Optica Therapy Product
Table 110. CBOP Revenue in Neuromyelitis Optica Therapy Business (2018-2024) & (US$ Million)
Table 111. CBOP Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuromyelitis Optica Therapy Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Neuromyelitis Optica Therapy Market Share by Type: 2022 VS 2029
Figure 3. Glucocorticoids Features
Figure 4. Immunotherapies Features
Figure 5. Other Features
Figure 6. Global Neuromyelitis Optica Therapy Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 7. Global Neuromyelitis Optica Therapy Market Share by Application: 2022 VS 2029
Figure 8. Acute Attack Case Studies
Figure 9. Remission Prophylactic Treatment Case Studies
Figure 10. Neuromyelitis Optica Therapy Report Years Considered
Figure 11. Global Neuromyelitis Optica Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Neuromyelitis Optica Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Neuromyelitis Optica Therapy Market Share by Region: 2022 VS 2029
Figure 14. Global Neuromyelitis Optica Therapy Market Share by Players in 2022
Figure 15. Global Top Neuromyelitis Optica Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Therapy as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Therapy Revenue in 2022
Figure 17. North America Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Neuromyelitis Optica Therapy Market Share by Country (2018-2029)
Figure 19. United States Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Neuromyelitis Optica Therapy Market Share by Country (2018-2029)
Figure 23. Germany Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Neuromyelitis Optica Therapy Market Share by Region (2018-2029)
Figure 31. China Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Neuromyelitis Optica Therapy Market Share by Country (2018-2029)
Figure 39. Mexico Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Neuromyelitis Optica Therapy Market Share by Country (2018-2029)
Figure 43. Turkey Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Neuromyelitis Optica Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Pfizer Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 46. Fresenius Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 47. Teva Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 48. Sandoz Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 49. Intas Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 50. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 51. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 52. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 53. Baxter Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 54. CSL Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 55. Grifols Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 56. Octapharma Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 57. CBOP Revenue Growth Rate in Neuromyelitis Optica Therapy Business (2018-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed